



Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	AFT Pharmaceuticals Limited
Date this disclosure made:	22 December 2015
Date on which issuer listed or appointment made:	22 December 2015

Director or senior manager giving disclosure

Full name:	David Mark Flacks
Name of listed issuer:	AFT Pharmaceuticals Limited
Name of related body corporate (if applicable):	Not applicable
Position held in listed issuer:	Director

Summary of relevant interest (excluding specified derivatives)

Class of quoted financial product:	Fully paid ordinary shares
Nature of relevant interest:	Joint registered holder and beneficial owner as trustee of the Waitemata Family Trust
Number held in class:	83,764
Current registered holder:	David Mark Flacks and Adina Rita Betty Halpern as trustees of the Waitemata Family Trust

Summary of specified derivatives relevant interest (if applicable)

Type of derivative:	Not applicable
Class of underlying financial products:	Not applicable
Details of derivative	
The notional value of the derivative (if any) or the notional amount of underlying products (if any):	Not applicable
A statement as to whether the derivative is cash settled or physically settled:	Not applicable
Maturity date of the derivative (if any):	Not applicable
Expiry date of the derivative (if any):	Not applicable
The price specified in the terms of the derivative(if any):	Not applicable
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Not applicable

For that derivative, -

Parties to the derivative:	Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	Not applicable

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	22-Dec-15
Name and title of authorised person:	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Limited